VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom D who wrote (3636)	12/4/1997 6:01:00 PM
From: squetch	Read Replies (1) of 9719

Some ENMD info, I read an article in 12/97 in Cancer Research "Human Angiostatin Inhibits Murine Hemangioendothelioma Tumor Growth in vivo." My impression was positive. It seemed to inhibit KMS. I am not sure but, this may have been first study which tested non metastized tumors. I would add the Robert Skerel (UoToronto) review in Nature seemed cautious to me. Paraphrasing he said due to the chronic nature of antiangiogenesis it would need to be oral to increase use, cost of biologically based drug would have to be worked out, and also prospects of long term toxic side effects would have to be addressed. Quote: "In short what is needed is antiangiogenesis equivalent of aspirin." The graphs in the Folkman article surprised me. There apeared to be an effect. After the first treatment why was the tumor volume peak higher than the first in all threee tumor types? Also after the treatment "appeared to work"(visivble lack of tumor growth), the tumor mass still reached ~1/5th of max volume in LLC. Interesting to me, a laydude.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next